leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 15:30:10 - browse：65784

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Paxlovid should be available without a positive Covid test

knowledge

WSS

All of Us, NIH's precision medicine initiative, gets a big boost

WHO recommends dropping component of many flu vaccines

Cigna to pay $172 million to settle Medicare Advantage fraud probe

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Prime Medicine says its gene editing passes test in monkeys

Coloradans with cystic fibrosis could lose access to Trikafta

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

New air purifier tech could be key to improving indoor air quality

Kidney transplant patients stopped immunosuppressants in trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

DeepMind touts AlphaFold's new skills as protein folding AI models face off

United colonoscopy coverage change 'may cost lives,' doctors say

Sudafed saga points to U.S. issues with evaluating older drugs

BioMarin wins approval for gene therapy to treat hemophilia A

After Sarepta trial failure, Duchenne families brace for more debate

How one medical school became remarkably diverse

Gene therapy’s promise and the high cost of hope

leisure time

Bill would allow buprenorphine prescription for addiction via telehealth

How to convince healthy people to buy insurance

Menendez indictment could see pharma lose a key ally

Prime Medicine says its gene editing passes test in monkeys

Would Medicare drug price negotiations stall in a shutdown?

Kaiser Permanente unions announce official strike date

knowledge

knowledge

hotspot

focus